BENEFICIAL EFFECTS OF TREATMENT WITH TOCILIZUMAB IN MODERATE TO CRITICALLY ILL COVID-19 PATIENTS

MA Rana; MS Hashmi; R Pervaiz; A Qayyum; MMU Saif; MF Munir; MM Hafeez

doi:10.54112/pjicm.v2021i1.9

Authors

MA Rana 1. Head Department of Critical Care, Division of Medicine, Bahria International Hospital, Lahore, Pakistan.
MS Hashmi 2. Consultant Physician, Department of Critical Care, Division of Medicine, Bahria International Hospital, Lahore, Pakistan.
R Pervaiz 3. Senior Registrar, Department of Critical Care, Division of Medicine, Bahria International Hospital, Lahore, Pakistan.
A Qayyum 4. Head Department of Nephrology, Division of Medicine, Bahria International Hospital, Lahore, Pakistan.
MMU Saif 5. Department of Critical Care Nursing, Division of Medicine, Bahria International Hospital, Lahore, Pakistan.
MF Munir 5. Department of Critical Care Nursing, Division of Medicine, Bahria International Hospital, Lahore, Pakistan.
MM Hafeez 6. Department of Research & Development, Expert Doctor PVT, LTD, Lahore Pakistan

DOI:

https://doi.org/10.54112/pjicm.v2021i1.9

Keywords:

SARS-CoV-2, COVID-19, Inflammatory markers, PF ratio, TOCILIZUMAB

Abstract

Introduction: COVID-19 virus initiates an inflammatory response in the body involving many cytokines. Interluukin-6 (IL-6) is one of them, elevated levels of which found to be directly related to morbidity and mortality of infected patients. The aim of the current study was to evaluate the clinical benefits of Tocilizumab, a monoclonal antibody against interleukin-6 receptor, as a therapeutic agent for the treatment of Coronavirus disease 2019. Methods: The current retrospective study was conducted at Bahria Town International hospital from rom May 1^st to 5^thJuly 2020. Total of one twenty (n=120) moderate to severely ill patients (94 males and 26 females), infected with SARS-CoV-2 virus, were included to assess the effect of TOCILIZUMAB in improvement of PF ratio and other biochemical variables of prognostic importance, including CRP, serum ferritin levels, D-dimers and LDH. These parameters were compared before and after the ten days of treatment with tocilizumab. Demographic, laboratory and clinical finding were recorded for the feather analyses. Statistical analysis was performed by using software SPSS version 21.0. The Wilcoxon signed‐rank test used to compare parameters whenever appropriate. A P‐value of less than .05 was considered statistically significant. Results: The results of our study showed statistically significant improvement in PF ratio and decrease in CRP levels. Other parameters such as D-Dimer, Serum ferritin levels and LDH showed no change before and after treatment with tocilizumab. Conclusion: In summary, TOCILIZUMAB improved the PF and CRP ratio in COVID-19 patients, but other markers did not improve in response to TOCILIZUMAB in critically ill COVID-19 patients.

References

Ali, J., Ali, Q., Hafeez, M. M., and Malik, A. (2020). CLINICAL FEATURES, DIAGNOSIS AND TREATMENT OF COVID-19. Biological and Clinical Sciences Research Journal 2020.

Bedford, J., Enria, D., Giesecke, J., Heymann, D. L., Ihekweazu, C., Kobinger, G., Lane, H. C., Memish, Z., Oh, M.-d., and Schuchat, A. (2020). COVID-19: towards controlling of a pandemic. The Lancet 395, 1015-1018.

Chen, X., Zhao, B., Qu, Y., Chen, Y., Xiong, J., Feng, Y., Men, D., Huang, Q., Liu, Y., and Yang, B. (2020). Detectable serum SARSCoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clinical Infectious Diseases.

Guan, W.-j., Ni, Z.-y., Hu, Y., Liang, W.-h., Ou, C.q., He, J.-x., Liu, L., Shan, H., Lei, C.-l., and Hui, D. S. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine 382, 17081720.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., and Gu, X. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet 395, 497-506.

Khiali, S., Khani, E., and Entezari‐Maleki, T. (2020). A Comprehensive Review of Tocilizumab in COVID‐19 Acute Respiratory Distress Syndrome. The Journal of Clinical Pharmacology 60, 1131-1146.

Le, R. Q., Li, L., Yuan, W., Shord, S. S., Nie, L., Habtemariam, B. A., Przepiorka, D., Farrell, A. T., and Pazdur, R. (2018). FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell‐induced severe or life‐threatening cytokine release syndrome. The oncologist 23, 943.

Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D., and Li, J. (2020). Tocilizumab treatment in COVID‐19: A single center experience. Journal of medical virology 92, 814-818.

Mady, A. F., Ramdan, O., Al Yousef, R., Ishag, A., Bakirova, G., Kuhail, A., Shahzad, S., ElEtreby, W., Mumtaz, S., Almozainy, S., Palacio, K., Aldamahshi, D., Alcazar, A., Alodat, M., Abdelrahman, B., and Harthy, A. (2020). COVID 19 CRITICAL CARE TRAINING SURGE EXPERIENCE FOR PHYSICIANS IN RIYADH HEALTH CLUSTER ONE, SAUDI ARABIA. Biological and Clinical Sciences Research Journal 2020.

Melody, M., Nelson, J., Hastings, J., Propst, J., Smerina, M., Mendez, J., and Guru, P. (2020). Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019. Immunotherapy.

Moreno-Pérez, O., Andres, M., Leon-Ramirez, J.-M., Sánchez-Payá, J., Rodríguez, J. C., Sánchez, R., García-Sevila, R., Boix, V., Gil, J., and Merino, E. (2020). Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study. Journal of autoimmunity, 102523.

Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., and Wang, W. (2020). Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical Infectious Diseases.

Ruan, Q., Yang, K., Wang, W., Jiang, L., and Song, J. (2020). Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine 46, 846-848.

Shi, Y., Wang, Y., Shao, C., Huang, J., Gan, J., Huang, X., Bucci, E., Piacentini, M., Ippolito, G., and Melino, G. (2020). COVID-19 infection: the perspectives on immune responses. Nature Publishing Group.

Siddique, A., Fateh, A., Idrees, N., Ali, Q., Hafeez, M. M., and Malik, A. (2020). THE EPIDEMICS OF COVID-19. Biological and Clinical Sciences Research Journal 2020.

Tabassum, S. A., Bibi, T., Tariq, F., Tariq, S., Raza, S., Hafeez, M. M., and Rana, M. A. (2020). UNUSUAL LEUKEMOID REACTION IN A COVID-19 PATIENT: A CASE REPORT. Biological and Clinical Sciences Research Journal 2020.

Wu, Z., and McGoogan, J. M. (2020). Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama 323, 1239-1242.

Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., and Zhu, L. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine 8, 420-422